Erlotinib Plus WBRT Effective for NSCLC Brain Metastases
The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer. (Source: Cancer Network)
Source: Cancer Network - February 7, 2013 Category: Cancer & Oncology Source Type: news
FDA Approves Supplemental New Drug Application for Tarceva: Now,...
On January 16th 2013, Astellas Pharma announced that the FDA has accepted for filing a sNDA for Tarceva for first-line use in people with locally advanced or metastatic non-small cell lung cancer...(PRWeb January 30, 2013)Read the full story at http://www.prweb.com/releases/2013/1/prweb10372778.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 30, 2013 Category: Pharmaceuticals Source Type: news
FDA accepts supplemental New Drug Application for erlotinib tablets as first line treatment of NSCLC with EGFR activating mutations
Source: BioSpace
Area: News
The FDA has accepted for filing a supplemental New Drug Application (sNDA) for erlotinib for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) activating mutations. A pre-market approval (PMA) application for a companion diagnostic, the cobas® EGFR Mutation Test developed by Roche Molecular Diagnostics, has also been submitted to the FDA.
The sNDA submission is based on results of the phase III international EURTAC (European Randomised Trial of Tarceva vs. Chemotherapy) trial, e...
Source: NeLM - News - January 17, 2013 Category: Drugs & Pharmacology Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
VeriStrat ® Results Correlate with Survival Outcomes in Kidney Cancer Patients
< p > Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent ®) and erlotinib (Tarceva®), by survival outcomes. < /p > < p > 10/17/2011 < /p > (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 17, 2011 Category: Urology & Nephrology Source Type: news
Notes from the Eigth International Kidney Cancer Symposium
Conclusions on Optimal Systemic Control For High Risk Patients:
- Anti-angiogenic agents are capable of reducing primary tumors, but not consistently.
- There is no evidence that anti-angiogenic agents are anti-metastatic
- Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs
As a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicia...
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news
Notes from the Eigth International Kidney Cancer Symposium
Conclusions on OptimalSystemic Control For High Risk Patients: - Anti-angiogenic agents are capable of reducing primary tumors, but not consistently. - There is no evidence that anti-angiogenic agents are anti-metastatic - Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs As a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians&hel...
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news
Patient Advocate's Notes From 8th International Kidney Cancer Symposium
Conclusions on OptimalSystemic Control For High Risk Patients: - Anti-angiogenic agents are capable of reducing primary tumors, but not consistently. - There is no evidence that anti-angiogenic agents are anti-metastatic - Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs AS a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians... an example ...
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news
